

**LACK OF ASSOCIATION BETWEEN GASTRIC CANCER AND *HOPQ* ALLELES
IN *Helicobacter pylori***

Elham KAZEMI¹ and Danial KAHRIZI^{2,3*}

- 1-Department of Sexual Medicine, The Rhazes Center for Research in Family Health and Sexual Medicine; Kermanshah University of Medical Sciences, Kermanshah, Iran
2. Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
- 3- Department of Agronomy and Plant Breeding, Faculty of Agriculture, Razi University, Kermanshah, Iran

Kazemi E. and D. Kahrizi (2016): *Lack of association between gastric cancer and HOPQ alleles in Helicobacter pylori.* - Genetika, Vol 48, No.3, 893- 902.

Helicobacter pylori use a number of mechanisms to survive in the stomach lumen. The presence of these bacteria in the stomach can lead to gastritis and reduction in stomach acid production. Acute inflammation can directly damage to the peripheral cells that are responsible for the secretion of acid. The risk of developing gastric carcinoma is associated to heterogeneity of *Helicobacter pylori* virulence factors (such as *cagA*). The *HopQ* is one of the outer membrane proteins involved in bacterial adherence to gastric mucosa and has been suggested to also play a role in the virulence of *H. pylori*. This gene has been shown in two types. The purpose of the current study was to investigate the association between different *H. pylori* virulence *hopQ* alleles (types I and II) and patients with gastroduodenal disorders. For this purpose 58 stomach biopsies the of patients with gastric cancer and 100 saliva samples from healthy individuals were collected. Then genomic DNA was purified and PCR for was done for desired genes via specific primers. The *H. pylori* infections were diagnosed by PCR for *GlmM* gene. Then frequencies of *hopQI*⁺, *hopQII*⁺ and *hopQI*⁺ *hopQII*⁺ genotypes were determined in *H. pylori* infected cases. Statistical analysis showed that there were not significant differences between healthy and diseased ones for genotypes *hopQI*⁺, *hopQII*⁺ and *hopQI*⁺ *hopQII*⁺.

Keywords: gastric cancer, *HopQ* genotyping, *Helicobacter pylori*

Corresponding author: Danial Kahrizi, Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Email: dkahrizi@yahoo.com, Tel: +98 918 3322235, Fax: +98 83 3832 10 83

INTRODUCTION

Gastric cancer is the most universal lethal cancer with around 738,000 deaths per year (JEMAL *et al.*, 2011). Different frequency of gastric cancer in worldwide can be due to diversity in the genetic conditions, nutritional behaviors and living conditions (HUMANS, 1994).

Helicobacter pylori is a gram negative and successful gastric pathogen which colonizes more than 50% of the world population (COVER and BLASER, 2009).

The *H. pylori* infection is the key cause of gastric and duodenal ulcers, as well as a potential risk factor for gastric cancer and mucosa-associated tissue lymphoma (GRAHAMAND and FISCHBACH, 2010). Available information indicates a slight association between gastroduodenal diseases and *H. pylori* virulence factors (ZHOU *et al.*, 2004).

The *H. pylori* is now recognized to be a significant co-factor in the aetiology of non-cardia gastric cancer of both the diffuse and intestinal histological type. The latter type develops via a complex multistage and multifactorial process. The first stage involves progression from superficial gastritis to atrophic pangastritis with intestinal metaplasia and correlated hypochlorhydria. This gastric phenotype may then progress to dysplasia and gastric cancer. Many co-factors are concerned in this progression as well as the strain of *H. pylori*, host genetic factors, host gender and environmental factors. Intestinal colonization with helminthic infection may retard the progression by changing the immune and inflammatory response to *H. pylori* and colonization of the achlorhydric stomach with nitrosating bacteria may promote progression to cancer. *H. pylori* appears to be a necessary co-factor in the aetiology of most gastric cancers. Therefore, avoidance of the infection or its eradication in early life should reduce the occurrence of this widespread and usually fatal tumor (MCCOLL and EL-OMAR, 2002).

If *H. pylori* infects the gastric epithelium cells, the interleukin-8 should be induced and production of too much amounts of toxic reactive oxygen species (ROS) may be occurred. It may induce the interferon- γ (IFN- γ), tumor necrosis factor- α (TNF- α) and some other interleukins (AUGUSTO *et al.*, 2007). Oxidative stress that caused by ROS is involved in human carcinogenesis (CERUTTI, 1985). ROS generated in normal respiration of cells and during xenobiotics metabolism. It is known as a candidate agent in the growth of cancer and damage to cell membranes, mitochondria and DNA molecule (EGAN *et al.*, 2003).

Several putative virulence factors for *H. pylori* have been identified including *vacA*, *babA*, and *iceA*. *HopQ* is one of the outer membrane proteins involved in bacterial adherence to gastric mucosa and has been found as a virulence factor of *H. pylori*. In 2005, Cao *et al.*, reported that *H. pylori hopQ* genotypes are associated with an increased risk for peptic ulcer disease (CAO *et al.*, 2005). The *H. pylori* genomes include about 30 different *hop* genes, which encode outer membrane proteins (CAO and COVER, 2002).

LOH *et al.*, (2008) showed that, in certain *H. pylori*, adherence to the gastric epithelial cells are faintly facilitated in strains expressing *hopQ* (Loh *et al.*, 2008), though they did not present further data about disease specific virulence factor of *hopQ*.

The high rate of *H. pylori* infection in Iran and the increasing number of digestive complaints lead to the current study on whether the presence of *hopQ* (type I and II) can affect disease outcome.

The purpose of the current study was to investigate the association between different *H. pylori* virulence *hopQ* alleles (types I and II) and patients with gastroduodenal disorders among a sample of the Iranian population.

MATERIALS AND METHODS

Materials, chemicals and reagents

Agarose and polymerase chain reaction (PCR) materials were prepared from Fermentas. Specific primers were synthesized by Cinnacolon, Iran. All chemicals and reagents were prepared from Zagros Bioidea Co, Kermanshah, Iran.

Participants

The population consisted of gastric cancer patients and cancer-free as controls. All desired population was *H. pylori* infected. Gastric biopsies were taken from 58 gastric cancer patients and 100 cancer-free that were infected to *H. pylori*. The patients and controls were age and sex matched. The experiment materials included stomach biopsies of the patients with gastric cancer and saliva samples from healthy individuals.

DNA purification and gene amplification

The genomic DNA was purified from stomach biopsies of the patients with gastric cancer (according to MORADI *et al.*, 2014 method) and saliva samples from buccal epithelial cells of the healthy individuals (according to AIDAR, 2007 method).

The PCR was done for desired genes via specific primers (Table 1). The *H. pylori* infections were diagnosed by PCR for *glmM* gene. Then frequencies of *hopQI*⁺, *hopQII*⁺ and *hopQI*⁺ *hopQII*⁺ genotypes were determined in *H. pylori* infected cases. All materials amount and conditions for PCR reactions are shown in tables 2 and 3.

The presence of *H. pylori* and *hopQ* alleles in gastric biopsy specimens and in saliva healthy samples was identified by specific PCR assays.

Statistical analysis

The χ^2 analysis was applied for study of different frequency in patients and healthy people. The SPSS V19 was used for Statistical analysis

Table 1. Primer sequences and amplified fragment length for *H. pylori* genes

Gene	Accession No.	Primer sequence	Amplified fragment length
<i>glmM</i>	900169	5'-AAGCTTTTAGGGGTGTTAGGGGTTT-3' 5'-AAGCTTACTTTCTAACACTAACGC-3'	294 bp
<i>hopQ1</i>	7010294	5'-ACGAACGCGCAAAAACCTTTA-3' 5'-TTGCCATTCTCATCGGTGTA-3'	187 bp
<i>hopQ2</i>	8208107	5'-ACAGCCACTCCAATCCAGAA-3' 5'-TTGACCAACAACCACAAACCGAAG-3'	160 bp

Table 2. Materials amount for all PCR reaction in current experiment

Materials	Amounts
MgCl ₂	1.5 mM
dNTP	200 mM
PCR Buffer	50 mM
F-Primer	50 pmol
R-Primer	50 pmol
Template DNA	2 µl
<i>Taq</i> DNA Polymerase	1 unit
Double distilled water	16.25µl
Total volume	25µ l

Table 3. Thermal cycles for PCR reaction for different *H. pylori* genes

Gene	Thermal cycles for PCR reaction				
	1	2	3	4	5
<i>glmM</i>	94°C (5 min)	94°C (30 sec)	58°C(30 sec)	72°C (30 sec)	72°C(5 min)
<i>hopQ1, hopQ2</i>	94 °C(5min)	94 °C(30sec)	54 °C(30sec)	72 °C(30sec)	72 °C(5min)

RESULTS

Genomic DNA purification

Genomic DNA from 58 gastric cancer patients and 100 cancer-free was purified successfully (Fig. 1). The quality and quantity of purified genomic DNA was studied via spectrophotometry.

Identification of *H. pylori* infected samples via *glmM* gene PCR amplification

The *H. pylori* infections were identified by PCR for *glmM* gene. The PCR reaction for this gene amplified a fragment in 294 bp length in the *H. pylori* infections (Fig 2.).




Figure 1. Purified genomic DNA from *H. pylori* infected samples. Lane 1: Size marker. Lane 2: genomic DNA.




Figure 2. Diagnosis of *H. pylori* from biopsy specimens and normal samples. PCR products and agarose gel electrophoresis for *glmM* gene detection from *H. pylori* infected samples. Lane 1: *glmM* gene amplification in gastric cancer patients. Lane 2: PCR product for *glmM* gene in cancer-free. Lane 3: Size marker. Lane 4: Negative control.

Polymerase chain reaction for *hopQI* gene detection:

The agarose gel electrophoresis for *hopQI* gene detection in the *H. pylori* infections via PCR has been shown in Fig. 3. The PCR reaction for this gene in *hopQI*⁺ samples amplified a fragment in 187 bp.




Figure 3. The agarose gel electrophoresis for *hopQI* gene amplification in the *H. pylori* infections via PCR. Lanes 1 and 2: *hopQI*⁻ strains. Lanes 3-6: *hopQI*⁺ strains. Lane 7: Negative control. Lane 8: DNA size marker.

The hopQI gene frequency in the H. pylori infections

The frequencies for the *hopQI* gene frequency in the *H. pylori* infections has been shown in table 4. The χ^2 analysis showed that there was not a significant difference between gastric cancer and healthy individuals for presence of allele in their strains ($P < 0.05$).

Table 4. The *hopQI* gene frequency in the *H. pylori* infections

	<i>hopQI</i> ⁺ (%)	<i>hopQI</i> ⁻ (%)
Case	53.8	46.2
Normal	46.4	53.6

P value = 0.308

Polymerase chain reaction for hopQII gene detection

The agarose gel electrophoresis for *hopQII* gene detection in the *H. pylori* infections via PCR has been shown in Fig. 4. The PCR reaction for this gene in *hopQII*⁺ samples amplified a fragment in 160 bp.




Figure 4. The agarose gel electrophoresis for *hopQII* gene amplification in the *H. pylori* infections via PCR. Lanes 1: DNA size marker. Lane 2 and 3: *hopQII*⁻ strains. Lane 4: Negative control. Lane 5: *hopQII*⁺ strains.

The hopQII gene frequency in the H. pylori infections

The frequencies for the *hopQII* gene frequency in the *H. pylori* infections has been shown in table 5. The χ^2 analysis showed that there was not a significant difference between gastric cancer and healthy individuals for presence of allele in their strains ($P < 0.05$).

Table 5. The *hopQII* gene frequency in the *H. pylori* infections

	<i>hopQII</i> ⁺ (%)	<i>hopQII</i> ⁻ (%)
Case	43.6	56.4
Normal	42.9	57.1

P value = 0.555

The hopQI hopQII genes simultaneously frequency in the H. pylori infections

The frequencies for the *hopQI* *hopQII* genes frequency as simultaneously in the *H. pylori* infections has been shown in table 6. The χ^2 analysis showed that there was not a significant difference between gastric cancer and healthy individuals for presence of allele in their strains ($P < 0.05$).

	<i>hopQ1</i> ⁺ , <i>hopQ1</i> ⁺ (%)	Others (%)
Case	23.1	76.9
Normal	10.3	89.7

P value =0.067

Table 6. The *hopQ1* *hopQ2* gene simultaneously frequency in the *H. pylori* infections

DISCUSSION

Gastric cancer is the most numerous diseases diagnosed in worldwide and it is the most common lethal cancer in Iran. Epidemiologic investigations have reported frequent risk factors for gastric cancer, including environmental, genetic factors, adverse living conditions, dietary habits and the prevalence of *Helicobacter pylori* infection (MOGES *et al.*, 2006).

Helicobacter pylori plays a key role in the pathogenesis of chronic gastritis, peptic ulceration, and noncardia gastric cancer. As it has been shown in Fig. 2, the PCR product from gastric cancer patients biopsies (lane 1) was more efficient rather than saliva samples from healthy individuals (lane 2).

Clinical development of *H. pylori* infection is affected by the interaction of numerous virulence factors as well as by the host. The *H. pylori* infection is the key causative agent of superficial gastritis and confirms an expected role in the etiology of peptic ulcer disease (GATTI *et al.*, 2005).

According to the biologic concepts, achieving successful and long term colonization requires composite adhesion mechanisms for bacteria. Therefore, all potential bacterial products were under focus for investigating the possible contribution in bacterial colonization. The *H. pylori* *HopQ* is one of the main outer membrane proteins on the bacterial surface and is the major outer membrane protein family observed in *H. pylori* genome. Determining a link between *H. pylori* *hopQ* and convinced digestive diseases may provide a start point for answering questions regarding *H. pylori* adherence to gastric cells. This study was designed to determine the frequency of *H. pylori* *hopQ* genotypes isolated from biopsy specimens. Our findings demonstrate a moderate prevalence of *H. pylori* *hopQ* types I and II genotype among Iranian patients with gastric cancer and healthy individuals that are infected to *H. pylori*. TALEBI BEZMIN ABADI and MOHABBATI MOBAREZ (2014) reported a high prevalence of *H. pylori* *hopQ* type II genotype among Iranian patients with gastric cancer that is not according to our finding.

It has been suggested that specific genotyping-based analysis of *H. pylori* isolates can be helpful for predicting post infection disorders (LU *et al.*, 2005).

Recent findings have shown that the *hopQ* type I allele is strongly associated with an increased risk of peptic ulcer diseases (PUD) in western countries and that *H. pylori* *hopQ* II is frequently detected among investigated population (OHNO *et al.*, 2009).

Furthermore, outer membrane proteins of *H. pylori* have shown a strong potential for increasing the severity of related gastroduodenal disorders. OHNO *et al.*, (2009) did not identify

any relationship between *hopQ* type I and II alleles and other virulence factors such as *cagA* and *vacA* in terms of clinical outcomes. Their finding is according to our results.

However, the exact relationship between virulence factors of *H. pylori* and *hopQ* alleles needs further investigation especially in genetically different populations.

In an investigation by OHNO *et al.*, (2009) the prevalence of *hopQ* I among gastritis and gastric cancer patients reported 58% and 68%, respectively. However, our results indicate that the frequency of *hopQ* I was almost similar in both *H. pylori* infected healthy individuals and gastritis patients (46.4% and 53.8%, resp.). TALEBI BEZMIN ABADI and MOHABBATI MOBAREZ (2014) reported that *hopQ* I is the less prevalent genotype among the *H. pylori* isolates recovered from the Iranian population. In contrast to a study from United States (CAO and COVER, 2002) which reported a significant association between the carriage of *H. pylori hopQ* type I among the peptic ulcer patients, OHNO *et al.*, (2009) did not identify a relationship between both *hopQ* alleles and clinical outcomes of infection ($P > 0.05$). It has been reported that *hopQ* type II strains have low frequency (less than 1%) among the Far East countries. Data from western countries indicate that the prevalence of *hopQ* type II strains (36%) is more common than countries from eastern Asia (1%). Our data about *hopQ* type II frequency is related to *H. pylori* infected persons not in a random population.

In conclusion, this study showed that *hopQ* I and II genotype is frequently present in *H. pylori* strains isolated from gastric cancer patients and healthy individuals in Iran. Then *hopQ* can not be a virulence and risk factor in our population

Received September 09th, 2015

Accepted June 18th, 2016

REFERENCES

- AIDAR, M. (2007): A simple and cost-effective protocol for DNA isolation from buccal epithelial cells. *Braz. Dent. J.*, *18*(2): 148-152.
- AUGUSTO, A.C., F. MIGUEL, S. MENDONÇA, J. PEDRAZZOLI, A. GURGUEIRA, (2007): Oxidative stress expression status associated to *Helicobacter pylori* virulence in gastric diseases. *Clin. Biochem.*, *40*: 615-22.
- CAO, P., T.L. COVER (2002): Two different families of *hopQ* alleles in *Helicobacter pylori*. *J. Clin. Microbiol.*, *40*: 4504-11.
- CAO, P., J.L. KERRY, M.J. BLASER, T.L. COVER (2005): Analysis of *hopQ* alleles in East Asian and Western strains of *Helicobacter pylori*. *FEMS Microbiol. Let.*, *251*(1): 37-43.
- CERUTTI, P.A. (1985): Prooxidant states and tumor promotion. *Science*, *227*: 375-81.
- COVER, T.L., M.J. BLASER (2009): *Helicobacter pylori* in health and disease. *Gastr.*, *136*(6):1863-1873.
- EGAN, K.M., P.A. THOMPSON, L.TITUS-ERNSTOFF, J.H. MOORE, C.B. AMBROSONE (2003). MnSOD polymorphism and breast cancer in a population-based case-control study. *Cancer let.*, *199*: 27-33.
- GATTI, L.L., E.K. FAGUNDES E SOUZA, K.R. LEITE (2005): *cagA vacA* alleles and *babA2* genotypes of *Helicobacter pylori* associated with gastric disease in Brazilian adult patients. *Diagn. Micr. Infec. Dis.*, *51*(4): 231-235.
- GRAHAMAND, D.Y., L. FISCHBACH (2010): *Helicobacter pylori* infection, *The New England J. Med.*, *363*(6): 595-596.
- HUMANS, I. (1994): Schistosomes, liver flukes and *Helicobacter pylori*, World Health Organization. Lyon, France.
- JEMAL, A., F. BRAY, M.M. CENTER, J. FERLAY, E. WARD, D. FORMAN (2011): Global cancer statistics. *CA: A Cancer J. Clinicians*, *61*: 69-90.
- LOH, J.T., V.J. TORRES, H.M. SCOTT ALGOOD, M.S. MCCLAIN, T.L. COVER (2008): *Helicobacter pylori HopQ* outer membrane protein attenuates bacterial adherence to gastric epithelial cells. *FEMS Micr. Let.*, *289*(1): 53-58.

- LU, H., Y. YAMAOKA, D.Y. GRAHAM (2005): *Helicobacter pylori* virulence factors: facts and fantasies," *Curr. Opin. Gastroen.*, 21(6): 653–659.
- MCCOLL, K.E., E. EL-OMAR (2002): How does *H. pylori* infection cause gastric cancer? *The Keio J. Med.*, 51(2):53-6.
- MOGES, F., A. KASSU, G. MENGISTU, S. ADUGNA, B. ANDUALEM, T. NISHIKAWA, F. OTA (2006): Seroprevalence of *Helicobacter pylori* in dyspeptic patients and its relationship with HIV infection, ABO blood groups and life style in a university hospital, Northwest Ethiopia. *World J. Gastroen.*, 12: 1957.
- MORADI, M.T., K. YARI, R. KHODARAHMI (2014): A novel, efficient, fast and inexpensive DNA extraction protocol from whole blood applicable for studying drug-DNA interaction. *J. Rep. Pharm. Sci.*, 3(1): 80-84.
- OHNO, T., M. SUGIMOTO, A. NAGASHIMA (2009): Relationship between *Helicobacter pylori* *hopQ* genotype and clinical outcome in Asian and Western populations. *J. Gastroen. Hepatolog.*, 24(3): 462–468.
- TALEBI BEZMIN ABADI, A., A. MOHABBATI MOBAREZ (2014): High prevalence of *Helicobacter pylori* *hopQ* II genotype isolated from Iranian patients with gastroduodenal disorders. *J. Pathogens*: 1-4.
- ZHOU, J., J. ZHANG, C. XU, L. HE (2004): *CagA* genotype and variants in Chinese *Helicobacter pylori* strains and relationship to gastroduodenal diseases. *J. Med. Micr.*, 53(3): 231–235.

ODSUSTVO POVEZANOSTI IZMEĐU GASTRIČNOG KANCERA I HOPQ ALELA KOD *Helicobacter pylori*

Elham KAZEMI¹ I Danial KAHRIZI^{2,3*}

¹Odeljenje za seksualnu medicinu, Rhazes Centar za istraživanje porodičnog zdravlja i seksualne medicine; Kermanshah Univerzitet medicinskih nauka, Kermanshah, Iran

² Istraživački centar za medicinsku biologiju, Kermanshah Univerzitet medicinskih nauka, Kermanshah, Iran

³ Odeljenje za agronomiju i oplemenjivanje biljaka, Poljoprivredni fakultet, Razi University, Kermanshah, Iran

Izvod

Helicobacter pylori koristi brojne mehanizme da preživi u stomačnom lumenu. Rizik od pojave karcinoma je povezan sa heterogenim *Helicobacter pylori* virulentnim faktorima (kao što je *cagA*). *HopQ* je jedan od spoljnih proteina membrane uključenih u prijanjanje bakterija na gastričnu mukožu i sugerisano je da takođe igra ulogu u virulentnosti *H. pylori*. Ovaj gen se javlja u dva oblika. Cilj ovih istraživanja je bio ispitivanje asocijacije različitih *H. pylori* virulence *hopQ* alela (tipovi I I II) i pacijenata sa poremećajima dfunkcije duodenuma. Za ova istraživanja analizirano je 58 uzoraka uzetih biopsijom pacijenata sa gastričnim kancerom i 100 uzoraka pljuvačnih žlezda uzetih od zdravih pacijenaata. Genomska DNA je izolovana i PCR analiza je izvršena za željene gene preko specifičnih prajmer sekvenci. *H. pylori* infekcija je dijagnostifikovana sa PCR za *GlmM* gene. Frekvencija *hopQI*⁺, *hopQII*⁺ i *hopQI*⁺ *hopQII*⁺ genotipova je determinisana u *H. pylori* inficiranim slučajevima. Statistička analiza je pokazala da nije bilo statistički značajnih razlika između zdravih i bolesnih za genotipove *hopQI*⁺, i *hopQI*⁺ *hopQII*⁺.

Priljeno 01. IX. 2015.

Odobreno 18. VI. 2016.